Discontinued — last reported Q4 '25
Investing
Acquisitions
Over 3 years (FY 2021 to FY 2024), Acquisitions shows a downward trend with a -26.8% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
Detailed definition
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Peer comparison
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
Metric ID:
cf_acquisitionsHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $52.25M | $52.25M | $52.25M | $170.25M | $170.25M | $170.25M | $170.25M | $3.25M | $3.25M | $3.25M | $3.25M | $20.50M | $20.50M | $20.50M | $20.50M | $0.00 | $596.00M |
| QoQ Change | — | +0.0% | +0.0% | +225.8% | +0.0% | +0.0% | +0.0% | -98.1% | +0.0% | +0.0% | +0.0% | +530.8% | +0.0% | +0.0% | +0.0% | -100.0% | — |
| YoY Change | — | — | — | — | +225.8% | +225.8% | +225.8% | -98.1% | -98.1% | -98.1% | -98.1% | +530.8% | +530.8% | +530.8% | +530.8% | -100.0% | — |
Range$0.00 – $596.00M
CAGR+83.8%
Avg YoY Growth+192.4%
Median YoY Growth+225.8%
Acquisitions at Other Companies
Frequently Asked Questions
- What is Intel's acquisitions?
- Intel (INTC) reported acquisitions of $596.00M in Q1 2026.
- What is the long-term trend for Intel's acquisitions?
- Over 3 years (2021 to 2024), Intel's acquisitions has grown at a -26.8% compound annual growth rate (CAGR), from $209.00M to $82.00M.
- What does acquisitions mean?
- Cash spent to acquire other companies or businesses, net of cash received in the deal.